The ALLOstery in Drug Discovery (ALLODD) project is a collaboration between 13 academic and industrial organizations with 14 ESR/PhD students available positions. The aim of ALLODD is to train a new generation of scientists to exploit the concept of allostery in drug design, putting together a whole array of technologies to identify and characterize allosteric modulators of protein function that will be applied to therapeutically relevant systems.

https://www.allodd-itn.eu/ 

The ALLODD Consortium consists of:

Biomedical Research Foundation Academy of Athens, Greece
University of Vienna, Austria
Universitat de Barcelona, Spain
Forschungszentrum Jülich, Germany
Charité - Universitätsmedizin Berlin, Germany
Research Center for Natural Sciences, Hungary
Forschungsverbund Berlin e.V., Germany
Karolinska Institutet, Sweden
Heptares LTD, UK
Université de Strasbourg, France
Merck Healthcare KGaA, Germany
Janssen Pharmaceutica NV, Belgium
University of Urbino, Italy

Partner Organisations of the ALLODD Consortium:

Bayer AG, Germany
EPISTIMI EPIKOINONIA, Greece
UCB Biopharma SRL, Belgium
Astex Therapeutics Limited, UK
Gain Therapeutics Sucursal en España, Spain
Novo Nordisk A/S, Denmark
Institute Pasteur, France
Budapest University of Technology and Economics, Hungary
University of Geneva, Switzerland
Confo Therapeutics NV, Belgium